StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of EVOK opened at $5.21 on Friday. The stock has a market capitalization of $7.76 million, a price-to-earnings ratio of -0.47 and a beta of 0.16. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $12.32. The business’s 50 day simple moving average is $4.65 and its 200-day simple moving average is $4.82.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.